Prediction of Optimal Cytoreductive Surgery of Serous Ovarian Cancer With Gene Expression Data

被引:9
作者
Abdallah, Reem [1 ]
Chon, Hye Sook [1 ]
Zgheib, Nadim Bou [1 ]
Marchion, Douglas C. [1 ]
Wenham, Robert M. [1 ]
Lancaster, Johnathan M. [1 ]
Gonzalez-Bosquet, Jesus [2 ]
机构
[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Gynecol Oncol Program,Dept Womens Oncol, Tampa, FL 33612 USA
[2] Univ Iowa Hosp & Clin, Dept Obstet & Gynecol, Gynecol Oncol, Iowa City, IA 52242 USA
关键词
Gene expression; Microarrays; Optimal debulking; Ovarian cancer; Suboptimal debulking; GYNECOLOGIC-ONCOLOGY-GROUP; EPITHELIAL OVARIAN; FALLOPIAN-TUBE; ACTIVIN-A; INTRAPERITONEAL CISPLATIN; SUBOPTIMAL CYTOREDUCTION; TUMOR HETEROGENEITY; SURVIVAL; CARCINOMA; CHEMOTHERAPY;
D O I
10.1097/IGC.0000000000000449
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives Cytoreductive surgery is the cornerstone of ovarian cancer (OVCA) treatment. Detractors of initial maximal surgical effort argue that aggressive tumor biology will dictate survival, not the surgical effort. We investigated the role of biology in achieving optimal cytoreduction in serous OVCA using microarray gene expression analysis. Methods For the initial model, we used a gene expression signature from a microarray expression analysis of 124 women with serous OVCA, defining optimal cytoreduction as removal of all disease greater than 1 cm (with 64 women having optimal and 60 suboptimal cytoreduction). We then applied this model to 2 independent data sets: the Australian Ovarian Cancer Study (AOCS; 190 samples) and The Cancer Genome Atlas (TCGA; 468 samples). We performed a second analysis, defining optimal cytoreduction as removal of all disease to microscopic residual, using data from AOCS to create the gene signature and validating results in TCGA data set. Results Of the 12,718 genes included in the initial analysis, 58 predicted accuracy of cytoreductive surgery 69% of the time (P = 0.005). The performance of this classifier, measured by the area under the receiver operating characteristic curve, was 73%. When applied to TCGA and AOCS, accuracy was 56% (P = 0.16) and 62% (P = 0.01), respectively, with performance at 57% and 65%, respectively. In the second analysis, 220 genes predicted accuracy of cytoreductive surgery in the AOCS set 74% of the time, with performance of 73%. When these results were validated in TCGA set, accuracy was 57% (P = 0.31) and performance was at 62%. Conclusion Gene expression data, used as a proxy of tumor biology, do not predict accurately nor consistently the ability to perform optimal cytoreductive surgery. Other factors, including surgical effort, may also explain part of the model. Additional studies integrating more biological and clinical data may improve the prediction model.
引用
收藏
页码:1000 / 1009
页数:10
相关论文
共 48 条
  • [1] Aggressive surgical effort and improved survival in advanced-stage ovarian cancer
    Aletti, GD
    Dowdy, SC
    Gostout, BS
    Jones, MB
    Stanhope, CR
    Wilson, TO
    Podratz, KC
    Cliby, WA
    [J]. OBSTETRICS AND GYNECOLOGY, 2006, 107 (01) : 77 - 85
  • [2] Intraperitoneal cisplatin and paclitaxel in ovarian cancer
    Armstrong, DK
    Bundy, B
    Wenzel, L
    Huang, HQ
    Baergen, R
    Lele, S
    Copeland, LJ
    Walker, JL
    Burger, RA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) : 34 - 43
  • [3] Expression and mutation of p53 in tumor effusion cells of patients with ovarian carcinoma: Response to cisplatin-based chemotherapy
    Bar, JK
    Harlozinska, A
    Popiela, A
    Noga, L
    [J]. TUMOR BIOLOGY, 2001, 22 (02) : 83 - 91
  • [4] Tumour heterogeneity in the clinic
    Bedard, Philippe L.
    Hansen, Aaron R.
    Ratain, Mark J.
    Siu, Lillian L.
    [J]. NATURE, 2013, 501 (7467) : 355 - 364
  • [5] Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays
    Berchuck, A
    Iversen, ES
    Lancaster, JM
    Dressman, HK
    West, M
    Nevins, JR
    Marks, JR
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2004, 190 (04) : 910 - 922
  • [6] Future directions in the surgical management of ovarian cancer
    Berman, ML
    [J]. GYNECOLOGIC ONCOLOGY, 2003, 90 (02) : S33 - S39
  • [7] A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer
    Bonome, Tomas
    Levine, Douglas A.
    Shih, Joanna
    Randonovich, Mike
    Pise-Masison, Cindy A.
    Bogomolniy, Faina
    Ozbun, Laurent
    Brady, John
    Barrett, J. Carl
    Boyd, Jeff
    Birrer, Michael J.
    [J]. CANCER RESEARCH, 2008, 68 (13) : 5478 - 5486
  • [8] Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis
    Bristow, RE
    Tomacruz, RS
    Armstrong, DK
    Trimble, EL
    Montz, FJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) : 1248 - 1259
  • [9] The causes and consequences of genetic heterogeneity in cancer evolution
    Burrell, Rebecca A.
    McGranahan, Nicholas
    Bartek, Jiri
    Swanton, Charles
    [J]. NATURE, 2013, 501 (7467) : 338 - 345
  • [10] Cancer Genome Atlas Research Network, 2011, Nature, V474